Your SlideShare is downloading. ×
Cardiovascular therapeutic drugs technologies and global markets
Cardiovascular therapeutic drugs technologies and global markets
Cardiovascular therapeutic drugs technologies and global markets
Cardiovascular therapeutic drugs technologies and global markets
Cardiovascular therapeutic drugs technologies and global markets
Cardiovascular therapeutic drugs technologies and global markets
Cardiovascular therapeutic drugs technologies and global markets
Cardiovascular therapeutic drugs technologies and global markets
Cardiovascular therapeutic drugs technologies and global markets
Cardiovascular therapeutic drugs technologies and global markets
Cardiovascular therapeutic drugs technologies and global markets
Cardiovascular therapeutic drugs technologies and global markets
Cardiovascular therapeutic drugs technologies and global markets
Cardiovascular therapeutic drugs technologies and global markets
Cardiovascular therapeutic drugs technologies and global markets
Cardiovascular therapeutic drugs technologies and global markets
Cardiovascular therapeutic drugs technologies and global markets
Cardiovascular therapeutic drugs technologies and global markets
Cardiovascular therapeutic drugs technologies and global markets
Cardiovascular therapeutic drugs technologies and global markets
Cardiovascular therapeutic drugs technologies and global markets
Cardiovascular therapeutic drugs technologies and global markets
Cardiovascular therapeutic drugs technologies and global markets
Cardiovascular therapeutic drugs technologies and global markets
Cardiovascular therapeutic drugs technologies and global markets
Cardiovascular therapeutic drugs technologies and global markets
Cardiovascular therapeutic drugs technologies and global markets
Cardiovascular therapeutic drugs technologies and global markets
Cardiovascular therapeutic drugs technologies and global markets
Cardiovascular therapeutic drugs technologies and global markets
Cardiovascular therapeutic drugs technologies and global markets
Cardiovascular therapeutic drugs technologies and global markets
Cardiovascular therapeutic drugs technologies and global markets
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Cardiovascular therapeutic drugs technologies and global markets

2,124

Published on

This study provides a comprehensive analysis of cardiovascular therapies on a global basis. Its aim is to provide a range of information, from detailed product analyses within disease subsegments to …

This study provides a comprehensive analysis of cardiovascular therapies on a global basis. Its aim is to provide a range of information, from detailed product analyses within disease subsegments to overall industry trends, in order to quantify and qualify the market for therapeutic drug products in the cardiovascular segment. Individual products are forecast on a global basis, as are overall segments.

Published in: Business, News & Politics
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
2,124
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
27
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Cardiovascular Therapeutic Drugs: Technologies and Global Markets.Report SummaryThe global cardiovascular therapeutic drug market was worth $140.7 billion in2009, and is expected to grow by a compound annual growth rate (CAGR) of 2.7%to $144.5 billion in 2010. This market will experience a sizable reduction in theearly portion of the forecast period, and then slowly rise to reach $139.8 billion in2015, a CAGR of -0.7%.The hypertension segment recorded $64.9 billion in sales in 2009. By a largemargin, hypertension is the largest segment within the cardiovascular market,driven by a large number of billion-dollar-plus therapies. The market is expected togrow to $65.3 billion in 2010 and experience a reduction through 2015 to $53.7billion, a compound annual growth rate (CAGR) of -3.9%.Treatment for hyperlipidemia recorded sales of more than $33 billion in 2009. Largetherapeutic drugs including Lipitor and Crestor comprise a high concentration of thissegment. Driven by patent expirations for Lipitor, and other drugs within thissegment, the segment will shrink to about $26 billion by 2015, a CAGR of -4.3%.INTRODUCTIONSTUDY GOALS AND OBJECTIVESThis study provides a comprehensive analysis of cardiovascular therapies on aglobal basis. Its aim is to provide a range of information, from detailed productanalyses within disease subsegments to overall industry trends, in order to quantifyand qualify the market for therapeutic drug products in the cardiovascular segment.Individual products are forecast on a global basis, as are overall segments.Forecasts and trends are developed from a cross-reference of data points, gleanedfrom proprietary industry sources, company publications, industry benchmarking,and other divergent data sources to arrive at a cogent and coordinated forecast.REASONS FOR DOING THE STUDYFor companies with an effective strategy, market opportunity awaits. Importantly,the ability to develop an effective strategy begins with where opportunity exists andends with how to effectively execute to capture profit from opportunity.The Cardiovascular Therapeutic Drug Market is the largest of any drug sector. Inaddition, companies that hold patent rights to the largest drug classes have electedto exit the sector, opening the market up to the next tier of participants.Market growth has been spurred by the introduction of differentiated therapies dueto novel mechanism of action, such as P2Y12 inhibitors and Factor Xa inhibitors. In
  • 2. contrast to technical innovation, patent expiry is producing a severe headwind asevidenced by Lipitor and Plavix which are expected to drop $19 billion in one-yearsales in 2015 from 2010.This study investigates one of the most important market drivers: the introductionof combination therapies, which are expected to continue to contribute substantiallyto market growth through the forecast period. Combination therapies forhypertension are anticipated, as evidenced by Valturna (Novartis, Diovan andTekturna) and Exforge (Novartis, Diovan and amlodipine).This report analyzes emerging markets, by disease segment. Continued growth isexpected in emerging geographies, driven by the growing middle class in emergingcountries such as India, China, Brazil and Russia.This report seeks to address the critically important topics of analyzing a changingmarket dynamic, emerging players and technologies, strategies for accessingemerging markets, and specific disease segments and geographies in order toallocate resources and make effective decisions.Browse All Pharmaceuticals Market Research ReportsSCOPE OF REPORTCurrent and projected product forecasts during the forecast period (2010 to 2015)are discussed. As well, new products approved in 2009 and 2010 by the FDA, andthose products expected to be approved within the forecast period are projected.2010 is an estimated figure, except where actual results have been reported, due tothe release timing of the report. For large markets segments such as hypertension,hyperlipidemia, and thrombosis, specific mechanisms of action are discussed indetail. For example, the trend of increased use of statins as a first-line therapy ascompared to beta blockers and heparin therapies is analyzed. For each coresegment within the overall market, leading products are analyzed for theirdifferentiation by mechanism of action. The attempt to pursue and seek approvalfor PDE5 inhibitors is discussed in detail.The report includes analysis of leading and emerging competitors in the currentworldwide cardiovascular market. Profiles of manufacturers of leading products aswell as biotechnology companies with novel products in development are analyzedto define their specific product strategies employed. This report also assessescompanies poised to introduce products during the forecast period and discusseshow these introductions will change the face of the competitive environment. Thecompetitive environment is examined with a special focus on how new products andtechnologies are influencing the current standard of care. Detailed profiles ofcurrent market leaders are discussed, as well as companies with innovativeproducts poised to advance within the forecast period.
  • 3. Market figures are based on revenues at the manufacturers’ level and are projectedat 2010-dollar value. Inflation is not computed into the projection figures. Trendsare assessed based on projected sales for existing products, new productintroductions, expanded indications for existing products, and projected changes inthe prevalence, diagnosis, and scripting rates for certain diseases.Included in this report are forecasts by product, product category, and by companyfrom 2009 through 2015. The study is arranged to offer an overview of thecardiovascular market accompanied by product, company, geography, andmechanism of action with forecasts broken down and covered by geographic regionor country. Virtually the entire globe is covered to include prevalence data, for eachdisease sub segment.Excluded from this report are over-the-counter (OTC) medications, and otherconsumables that do not require a physician’s prescription.Sales figures are reported in U.S. dollars and in each case reflect currencyfluctuations within the performance of revenue change. Revenue figures do notaccount for variation in local currencies.All market share data presented is on a global basis, unless specifically noted.INTENDED AUDIENCEThis report is an invaluable tool for business planners, acquisitions specialists,licensing strategists, product managers, market research analysts, investors,investor consultants and anyone interested in the cardiovascular market, itsproducts, its industry participants and its future.The importance of identifying overall market trends, product opportunities,emerging geographies, M&A opportunities and insights that provide guidance forsales growth or defensive moves cannot be overstated for a variety of constituents,including:* Established companies in the industry will benefit from the contents, includingcorporate strategy, sales and marketing, business development, and R&D.* Emerging biotechnology players in the segment must understand specificopportunities for out-licensing, originating from the elements of differentiation oftheir therapeutic drug as compared to leading, competitive, and emergingtherapies. As well, market forecasts can support investment, provided a thoroughand detailed substantiation is provided for the market forecast, as is found in thisstudy.* Investment firms evaluating candidates for venture capital or hedged investmentswill gain insights as to the opportunity and risks that are being encountered in theindustry, in a product and company specific analysis.* Equity analysts are provided detailed forecasts for the next 5 years, substantiated
  • 4. by quantitative analysis that can support further analysis to product and companyforecasts over the short and long run.METHODOLOGY AND INFORMATION SOURCESIn-depth interviews were conducted with leading experts in the field who areexecutives in companies, industry analysts, and leading medical practitioners in thefield.Information to prepare this report was obtained from participating and emergingcompanies in the cardiovascular area; American Heart Association, the NationalHeart, Lung and Blood Institute and the National Heart, Lung, and Blood Institute;articles published in medical journals such as American Heart Journal, Circulation,Journal of Cardiovascular Pharmacology, Lancet, and others; the World HealthOrganization and other government agencies; literature searches; annual reports;10Ks; and others. Population estimates are based on those reported by theInternational data base of the U.S. Census Bureau.Current and historical revenue figures for individual products have been sourcedfrom company disclosures that exist in the public domain or from governmentsources.Table of ContentsCHAPTER ONE: INTRODUCTION STUDY GOALS AND OBJECTIVES REASONS FOR DOING THE STUDY SCOPE OF REPORT INTENDED AUDIENCE METHODOLOGY AND INFORMATION SOURCES RELATED REPORTS BCC ONLINE SERVICES DISCLAIMERCHAPTER TWO: SUMMARY SUMMARY TABLE GLOBAL CARDIOVASCULAR FORECAST BY DISEASE CLASS, THROUGH 2015 ($ MILLIONS) SUMMARY FIGURE GLOBAL CARDIOVASCULAR FORECAST BY DISEASE CLASS, 2007-2015 ($ MILLIONS)
  • 5. CHAPTER THREE: OVERVIEWCURRENT STATE OF CARDIOVASCULAR DISEASE FIGURE 1 LEADING CAUSES OF DEATH IN THE UNITED STATES; 2006 (DEATHS PER 100,000)ESTABLISHED DRUG CLASSES IN CARDIOVASCULAR DISEASEStatinsAngiotensin Receptor BlockerAngiotensin Converting Enzyme (ACE) inhibitorsEMERGING DRUG CLASSESP2Y12 Inhibitors and AntagonistsFactor Xa InhibitorsCholesterol-Ester Transfer Protein (CETP) Inhibitor TABLE 1 CETP INHIBITORS IN ACTIVE DEVELOPMENTKEY RECENT EVENTS IN THE CARDIOVASCULAR MARKETPLAVIX METABOLIZER 2C19 TRIGGERS U.S. WARNINGVALTURNA IS FIRST TO RECEIVE U.S. APPROVAL AS COMBINATION THERAPY FORHYPERTENSIONSUMMARY PIPELINE OF DRUGS IN DEVELOPMENT TABLE 2 RECENTLY APPROVED DRUGS TABLE 3 SUMMARY PIPELINE FORECAST
  • 6. CHAPTER FOUR: INDUSTRY STRUCTURE AND COMPETITIVE ANALYSISINDUSTRY STRUCTURE TABLE 4 CARDIOVASCULAR MARKET SEGMENTS, SIZE, GROWTH AND SHARE, THROUGH 2010 ($ MILLIONS)MARKET CONCENTRATION AND PRICE SENSITIVITY TABLE 5 COMPANY BY DISEASE CLASS, 2010 REVENUE ($ MILLIONS)MARKET TRENDSOverall Market Flat: Higher Mix of Generics Offset by Higher Volume TABLE 6 PATENT EXPIRATION OF CARDIOVASCULAR DRUGS ($ MILLIONS)Massive Patent Expiration is a Growth Opportunity for GenericsMarket Expansion via Disease Prevention is the Future of Cardio CareAtrial Fibrillation is a Large and Emerging Disease StateCombination Therapies are Synergistic Revenue Generators TABLE 7 COMPANY BY DISEASE CLASS, 2015 REVENUE ($ MILLIONS) TABLE 8 MARKET SHARE BY LEADING CARDIOVASCULAR PLAYERS ($ MILLIONS) TABLE 9 LARGEST REVENUE GENERATING THERAPIES IN THE CARDIOVASCULAR SEGMENT, 2009 AND 2010 ($ MILLIONS)CHAPTER FIVE: MARKETS BY DISEASE
  • 7. SUMMARY OF MARKET DYNAMICS TABLE 10 GLOBAL CARDIOVASCULAR FORECAST BY DISEASE CLASS, THROUGH 2015 ($ MILLIONS)HYPERTENSIONPATHOPHYSIOLOGY AND PATHOGENESISPathophysiology and Pathogenesis (Continued) TABLE 11 HYPERTENSION STAGES AS MEASURED BY PRESSURE DIFFERENTIAL AT THE HEART (MMHG AND KILO-PASCAL)TREATMENT AND MANAGEMENT TABLE 12 CURRENT GLOBAL HYPERTENSION MARKET, 2007-2010 ($ MILLIONS)Diovan/Co-DiovanMicardisBenicarNorvascCozaar/Hyzaar TABLE 13 GLOBAL HYPERTENSION MARKET FORECAST, THROUGH 2015 ($ MILLIONS) TABLE 14 FORECAST EPIDEMIOLOGY: HYPERTENSIONHYPERLIPIDEMIA
  • 8. PATHOPHYSIOLOGY AND PATHOGENESISGenetic Factors in Hyperlipidemia TABLE 15 GENERAL CLASSIFICATION OF HYPERLIPIDEMIA (TRIGLYCERIDE AND TOTAL CHOLESTEROL) TABLE 16 FREDRICKSON CLASSIFICATION OF HYPERLIPIDEMIASTREATMENT AND MANAGEMENT TABLE 17 CURRENT GLOBAL HYPERLIPIDEMIA MARKET, 2007-2010 ($ MILLIONS)LipitorCrestorZetiaVytorin TABLE 18 GLOBAL HYPERLIPIDEMIA MARKET FORECAST, THROUGH 2015 ($ MILLIONS) TABLE 19 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIATHROMBOSISPATHOPHYSIOLOGY AND PATHOGENESIS TABLE 20 CURRENT GLOBAL THROMBOSIS MARKET, 2007-2010 ($ MILLIONS)TREATMENT AND MANAGEMENTPlavix
  • 9. Lovenox TABLE 21 GLOBAL THROMBOSIS MARKET FORECAST, THROUGH 2015 ($ MILLIONS)CARDIAC FAILURE DISEASEPATHOPHYSIOLOGY AND PATHOGENESISStroke TABLE 22 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015Cardiac ArrhythmiasAngina PectorisMyocardial Infarction (MI)Congestive Heart Failure (CHF)Acute Coronary Syndrome (ACS) TABLE 23 CURRENT GLOBAL CARDIAC FAILURE MARKET, 2007-2010 ($ MILLIONS)TREATMENT AND MANAGEMENTVastarelOther Drugs TABLE 24 GLOBAL CARDIAC FAILURE MARKET FORECAST, THROUGH 2015 ($ MILLIONS)OTHER CARDIOVASCULAR DISEASE
  • 10. PATHOPHYSIOLOGY AND PATHOGENESISPulmonary HypertensionPeripheral Artery Disease (PAD) TABLE 25 OTHER CARDIOVASCULAR DISEASE CURRENT GLOBAL MARKET ($ MILLIONS)TREATMENT AND MANAGEMENTTracleerOther Drugs TABLE 26 OTHER CARDIOVASCULAR GLOBAL MARKET FORECAST, THROUGH 2015 ($ MILLIONS)CHAPTER SIX: MARKETS BY DRUG CLASSSUMMARY OF MARKET DYNAMICS TABLE 27 CURRENT CARDIOVASCULAR MARKET BY DRUG CLASS, 2008-2010 ($ MILLIONS) TABLE 28 CARDIOVASCULAR MARKET FORECAST BY DRUG CLASS, THROUGH 2015 ($ MILLIONS)MONOTHERAPIESSTATINS TABLE 29 STATIN CURRENT MARKET GROWTH AND SHARE, 2007-2010 ($ MILLIONS)
  • 11. Genetic Influences to Statin Efficacy TABLE 30 STATIN DRUG DOSING AND LDL REDUCTION CORRELATION TABLE 31 STATIN MARKET FORECAST FOR HYPER-LIPIDEMIA, THROUGH 2015 ($ MILLIONS)ANGIOTENSIN RECEPTOR BLOCKER (ARB) TABLE 32 COMPARISON OF ARB PHARMACOKINETICS TABLE 33 ARB CURRENT MARKET FOR HYPERTYENSION, GROWTH AND SHARE, 2007-2010 ($ MILLIONS)Myocardial Infarction Risk Due to ARB InhibitionARB Impact on Alzheimer’s Disease Risk TABLE 34 ARB MARKET FORECAST FOR HYPERTENSION, THROUGH 2015 ($ MILLIONS)CALCIUM CHANNEL BLOCKERS (CCB) TABLE 35 CCB CURRENT MARKET FOR HYPERTENSION, GROWTH AND SHARE, 2007-2010 ($ MILLIONS) TABLE 36 CCB MARKET FORECAST FOR HYPERTENSION, THROUGH 2015 ($ MILLIONS)LOW MOLECULAR WEIGHT HEPARINS (LMWH) TABLE 37 LMWH CURRENT MARKET FOR THROMBOSIS, GROWTH AND SHARE, 2007-2010 ($ MILLIONS) TABLE 38 LMWH MARKET FOR THROMBOSIS, FORECAST, THROUGH 2015 ($ MILLIONS)ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITORS TABLE 39 ACE INHIBITORS FOR HYPERTENSION, GOWTH AND SHARE, 2007- 2010 ($ MILLIONS)
  • 12. TABLE 40 ACE INHIBITOR MARKET FORECAST FOR HYPERTENSION, THROUGH 2015 ($ MILLIONS)P2Y12 AND FACTOR XA INHIBITORSEffient (Prasugrel): a Leading P2Y12 Antagonist TABLE 41 P2Y12 CURRENT MARKET GROWTH AND SHARE, 2007-2010 ($ MILLIONS) TABLE 42 PY12 MARKET FORECAST, THROUGH 2015 ($ MILLIONS) TABLE 43 FACTOR XA CURRENT THROMBOIS MARKET GROWTH AND SHARE, 2007-2010 ($ MILLIONS) TABLE 44 FACTOR XA MARKET FORECAST, THROUGH 2015 ($ MILLIONS) COMBINATION DRUG CLASSESCHAPTER SEVEN: MARKETS BY GEOGRAPHYSUMMARY TABLE 45 CURRENT MARKET SIZE BY GEOGRAPHY, 2009 AND 2010 ($ MILLIONS)METHODOLOGY TABLE 46 MARKET FORECAST BY GEOGRAPHY, THROUGH 2015 ($ MILLIONS)UNITED STATES TABLE 47 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH 2015 (U.S.) TABLE 48 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH 2015 (U.S.) TABLE 49 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015 (U.S.)WESTERN EUROPE
  • 13. TABLE 50 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH 2015 (WESTERN EUROPE) TABLE 51 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH 2015 (WESTERN EUROPE) TABLE 52 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015 (WESTERN EUROPE)JAPAN TABLE 53 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH 2015 (JAPAN) TABLE 54 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH 2015 (JAPAN) TABLE 55 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015 (JAPAN)STRATEGIES TO ACCESS EMERGING MARKETSEMERGING MARKETS FORECASTBRAZILMARKET OVERVIEWREGULATORY CONSIDERATIONSPATENT CONSIDERATIONS TABLE 56 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH 2015 (BRAZIL) TABLE 57 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH 2015 (BRAZIL) TABLE 58 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015 (BRAZIL)CHINAMARKET OVERVIEWREGULATORY CONSIDERATIONS
  • 14. PATENT CONSIDERATIONS TABLE 59 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH 2015 (CHINA) TABLE 60 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH 2015 (CHINA) TABLE 61 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015 (CHINA)INDIAMARKET OVERVIEWREGULATORY CONSIDERATIONSPATENT CONSIDERATIONS TABLE 62 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH 2015 (INDIA) TABLE 63 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH 2015 (INDIA) TABLE 64 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015 (INDIA)RUSSIAMARKET OVERVIEWREGULATORY CONSIDERATIONSPATENT CONSIDERATIONS TABLE 65 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH 2015 (RUSSIA) TABLE 66 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH 2015 (RUSSIA) TABLE 67 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015 (RUSSIA)SOUTH AMERICA
  • 15. TABLE 68 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH 2015 (SOUTH AMERICA) TABLE 69 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH 2015 (SOUTH AMERICA) TABLE 70 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015 (SOUTH AMERICA)CARRIBEAN TABLE 71 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH 2015 (CARRIBEAN) TABLE 72 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH 2015 (CARRIBEAN) TABLE 73 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015 (CARRIBEAN)NORTHERN EUROPE TABLE 74 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH 2015 (NORTHERN EUROPE) TABLE 75 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH 2015 (NORTHERN EUROPE) TABLE 76 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015 (NORTHERN EUROPE)CENTRAL AND EASTERN EUROPE TABLE 77 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH 2015 (CENTRAL & EASTERN EUROPE) TABLE 78 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH 2015 (CENTRAL & EASTERN EUROPE) TABLE 79 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015 (CENTRAL & EASTERN EUROPE)AUSTRALIA TABLE 80 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH 2015 (AUSTRALIA) TABLE 81 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH 2015 (AUSTRALIA)
  • 16. TABLE 82 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015 (AUSTRALIA)ASIA-OTHER TABLE 83 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH 2015 (ASIA-OTHER) TABLE 84 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH 2015 (ASIA-OTHER) TABLE 85 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015 (ASIA- OTHER)MIDDLE EAST TABLE 86 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH 2015 (MIDDLE EAST) TABLE 87 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH 2015 (MIDDLE EAST) TABLE 88 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015 (MIDDLE EAST)SOUTHERN AFRICA TABLE 89 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH 2015 (SOUTHERN AFRICA) TABLE 90 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH 2015 (SOUTHERN AFRICA) TABLE 91 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015 (SOUTHERN AFRICA)AFRICAN REGIONS EXCLUDED FROM EPIDEMIOLOGY FORECASTCHAPTER EIGHT: PIPELINE ANALYSIS TABLE 92 APPROVED PRODUCT FORECAST, 2010 AND 2015 ($ MILLIONS)MARKET TRENDS ARISING FROM PIPELINE DEVELOPMENT
  • 17. VALTURNA IS FIRST TO RECEIVE U.S. APPROVAL AS COMBINATION THERAPY FORHYPERTENTIONANTICOAGULANTS ENABLE NEW PRODUCT APPROVALS, IN PARTICULAR FACTORXAP2Y12 IS A PROVEN TARGET FOR MULTIPLE INDICATIONS; APPROVALS AREEXPECTEDAPOB-100 AS A NOVEL TREATMENT FOR HYPERLIPIDEMIAINCREASED DRIVE TO ESTABLISH AND EXTEND HIGH HDL CHOLESTEROL LEVELS2009 APPROVALS IN CARDIOVASCULAR THERAPYMULTAQ (DRONEDARONE) - SANOFI-AVENTIS TABLE 93 MULTAQ SNAPSHOTXARELTO (RIVAROXABAN) - BAYER SCHERING/J&J TABLE 94 XARELTO SNAPSHOTEFFIENT/EFIENT (PRASUGREL) - ELI LILLY/DAIICHI SANKYO TABLE 95 EFFIENT SNAPSHOTRENDIX (DABIGATRAN) - BOEHRINGER INGELHEIM TABLE 96 RENDIX SNAPSHOTRECENTLY FILED/PRE-REGISTRATION COMPOUNDSAPIXABAN - BRISTOL-MYERS SQUIBB (BMS)/PFIZER TABLE 97 APIXABAN SNAPSHOT
  • 18. BRILINTA (TICAGRELOR/AZD6140) - ASTRAZENECA TABLE 98 BRILINTA SNAPSHOTCERTRIAD (ROSUVASTATIN/ FENOFIBRIC ACID) - ASTRAZENECA/ABBOTT TABLE 99 CERTRIAD SNAPSHOTPHASE II/III COMPOUNDSLCZ696 - NOVARTIS TABLE 100 LCZ696 SNAPSHOTEDOXABAN (DU-176B) - DAIICHI SANKYO TABLE 101 EDOXABAN (DU-176B) SNAPSHOTSCH 530348 - MERCK TABLE 102 SCH530348 SNAPSHOTTYRISA/DARAPLADIB - GSK TABLE 103 TYRISA SNAPSHOTBETRIXABAN - PORTOLA/MERCK TABLE 104 BETRIXABAN SNAPSHOTPIPELINE ANALYSIS BY COMPANY TABLE 105 PFIZER’S CARDIOVASCULAR PIPELINE TABLE 106 SANOFI-AVENTIS’ CARDIOVASCULAR PIPELINE TABLE 107 NOVARTIS’ CARDIOVASCULAR PIPELINE TABLE 108 MERCK’S CARDIOVASCULAR PIPELINE
  • 19. TABLE 109 BMS’ CARDIOVASCULAR PIPELINE TABLE 110 ASTRA-ZENECA’S CARDIOVASCULAR PIPELINECHAPTER NINE: COMPANY PROFILESSUMMARY TABLE 111 COMPANY REVENUE AND MARKET SHARE ANALYSIS, 2007-2009 ($ MILLIONS) TABLE 112 MARKET FORECAST BY COMPANY, THROUGH 2015 ($ MILLIONS)ABBOTT LABORATORIESBusiness OverviewCorporate StrategyACTELION LTD.Business OverviewLeading ProductsCorporate StrategyASTELLAS PHARMA, INC.Business OverviewLeading ProductsCorporate StrategyASTRAZENECABusiness OverviewLeading ProductsCrestorAtacand
  • 20. CertriadCorporate StrategyBAYER AGBusiness OverviewLeading ProductsAdalatBRISTOL-MYERS SQUIBB COMPANYBusiness OverviewLeading ProductsPlavixApixabanCorporate StrategyDAIICHI SANKYO, INC. (DAIICHI SANKYO GROUP)Business OverviewLeading ProductsBenicarEffientCorporate StrategyELI LILLY & CO.Business OverviewLeading ProductsFOREST LABORATORIES, INC.Business Overview
  • 21. Leading ProductsBenicarCorporate StrategyGILEAD SCIENCES, INC.Business OverviewLeading ProductsCorporate StrategyGLAXOSMITHKLINE (GSK)Business OverviewLeading ProductsArixtraCorporate StrategyMERCK & CO., INC.Business OverviewLeading ProductsVytorinZetiaCozaarHyzaarZocorCorporate StrategyMYLAN, INC.Business Overview
  • 22. Corporate StrategyNOVARTISBusiness OverviewLeading ProductsDiovanCo-DiovanExforgeCorporate StrategyPFIZER, INC.Business OverviewLeading ProductsLipitorNorvascRevatioCorporate StrategySANOFI AVENTISBusiness OverviewLeading ProductsPlavixLovenoxMultaqCorporate StrategyTAKEDA PHARMACEUTICAL COMPANY LIMITED
  • 23. Business OverviewLeading ProductsBlopressAtacand and Atacand PlusCorporate StrategyTEVA PHARMACEUTICAL INDUSTRIES LTDBusiness OverviewLeading ProductsClopidogrelCorporate StrategyTHE MEDICINES COMPANY, INC.Website: www.themedicinescompany.comBusiness OverviewLeading ProductsAngiomaxCorporate StrategyUNITED THERAPEUTICS CORPORATIONBusiness OverviewLeading ProductsRemodulinCorporate Strategy
  • 24. LIST OF TABLESSUMMARY TABLE GLOBAL CARDIOVASCULAR FORECAST BYDISEASE CLASS, THROUGH 2015 ($ MILLIONS)TABLE 1 CETP INHIBITORS IN ACTIVE DEVELOPMENTTABLE 2 RECENTLY APPROVED DRUGSTABLE 3 SUMMARY PIPELINE FORECASTTABLE 4 CARDIOVASCULAR MARKET SEGMENTS, SIZE, GROWTHAND SHARE, THROUGH 2010 ($ MILLIONS)TABLE 5 COMPANY BY DISEASE CLASS, 2010 REVENUE ($ MILLIONS)TABLE 6 PATENT EXPIRATION OF CARDIOVASCULAR DRUGS ($MILLIONS)TABLE 7 COMPANY BY DISEASE CLASS, 2015 REVENUE ($ MILLIONS)TABLE 8 MARKET SHARE BY LEADING CARDIOVASCULAR PLAYERS($ MILLIONS)TABLE 9 LARGEST REVENUE GENERATING THERAPIES IN THECARDIOVASCULAR SEGMENT, 2009 AND 2010 ($ MILLIONS)TABLE 10 GLOBAL CARDIOVASCULAR FORECAST BY DISEASECLASS, THROUGH 2015 ($ MILLIONS)TABLE 11 HYPERTENSION STAGES AS MEASURED BY PRESSUREDIFFERENTIAL AT THE HEART (MMHG AND KILO-PASCAL)TABLE 12 CURRENT GLOBAL HYPERTENSION MARKET, 2007-2010 ($
  • 25. MILLIONS)TABLE 13 GLOBAL HYPERTENSION MARKET FORECAST, THROUGH2015 ($ MILLIONS)TABLE 14 FORECAST EPIDEMIOLOGY: HYPERTENSIONTABLE 15 GENERAL CLASSIFICATION OF HYPERLIPIDEMIA(TRIGLYCERIDE AND TOTAL CHOLESTEROL)TABLE 16 FREDRICKSON CLASSIFICATION OF HYPERLIPIDEMIASTABLE 17 CURRENT GLOBAL HYPERLIPIDEMIA MARKET, 2007-2010($ MILLIONS)TABLE 18 GLOBAL HYPERLIPIDEMIA MARKET FORECAST,THROUGH 2015 ($ MILLIONS)TABLE 19 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIATABLE 20 CURRENT GLOBAL THROMBOSIS MARKET, 2007-2010 ($MILLIONS)TABLE 21 GLOBAL THROMBOSIS MARKET FORECAST, THROUGH2015 ($ MILLIONS)TABLE 22 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015TABLE 23 CURRENT GLOBAL CARDIAC FAILURE MARKET, 2007-2010($ MILLIONS)TABLE 24 GLOBAL CARDIAC FAILURE MARKET FORECAST,THROUGH 2015 ($ MILLIONS)TABLE 25 OTHER CARDIOVASCULAR DISEASE CURRENT GLOBALMARKET ($ MILLIONS)
  • 26. TABLE 26 OTHER CARDIOVASCULAR GLOBAL MARKET FORECAST,THROUGH 2015 ($ MILLIONS)TABLE 27 CURRENT CARDIOVASCULAR MARKET BY DRUG CLASS,2008-2010 ($ MILLIONS)TABLE 28 CARDIOVASCULAR MARKET FORECAST BY DRUG CLASS,THROUGH 2015 ($ MILLIONS)TABLE 29 STATIN CURRENT MARKET GROWTH AND SHARE, 2007-2010 ($ MILLIONS)TABLE 30 STATIN DRUG DOSING AND LDL REDUCTIONCORRELATIONTABLE 31 STATIN MARKET FORECAST FOR HYPER-LIPIDEMIA,THROUGH 2015 ($ MILLIONS)TABLE 32 COMPARISON OF ARB PHARMACOKINETICSTABLE 33 ARB CURRENT MARKET FOR HYPERTYENSION, GROWTHAND SHARE, 2007-2010 ($ MILLIONS)TABLE 34 ARB MARKET FORECAST FOR HYPERTENSION, THROUGH2015 ($ MILLIONS)TABLE 35 CCB CURRENT MARKET FOR HYPERTENSION, GROWTHAND SHARE, 2007-2010 ($ MILLIONS)TABLE 36 CCB MARKET FORECAST FOR HYPERTENSION, THROUGH2015 ($ MILLIONS)TABLE 37 LMWH CURRENT MARKET FOR THROMBOSIS, GROWTHAND SHARE, 2007-2010 ($ MILLIONS)
  • 27. TABLE 38 LMWH MARKET FOR THROMBOSIS, FORECAST, THROUGH2015 ($ MILLIONS)TABLE 39 ACE INHIBITORS FOR HYPERTENSION, GOWTH ANDSHARE, 2007-2010 ($ MILLIONS)TABLE 40 ACE INHIBITOR MARKET FORECAST FOR HYPERTENSION,THROUGH 2015 ($ MILLIONS)TABLE 41 P2Y12 CURRENT MARKET GROWTH AND SHARE, 2007-2010($ MILLIONS)TABLE 42 PY12 MARKET FORECAST, THROUGH 2015 ($ MILLIONS)TABLE 43 FACTOR XA CURRENT THROMBOIS MARKET GROWTHAND SHARE, 2007-2010 ($ MILLIONS)TABLE 44 FACTOR XA MARKET FORECAST, THROUGH 2015 ($MILLIONS)TABLE 45 CURRENT MARKET SIZE BY GEOGRAPHY, 2009 AND 2010 ($MILLIONS)TABLE 46 MARKET FORECAST BY GEOGRAPHY, THROUGH 2015 ($MILLIONS)TABLE 47 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH2015 (U.S.)TABLE 48 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH2015 (U.S.)TABLE 49 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015(U.S.)
  • 28. TABLE 50 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH2015 (WESTERN EUROPE)TABLE 51 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH2015 (WESTERN EUROPE)TABLE 52 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015(WESTERN EUROPE)TABLE 53 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH2015 (JAPAN)TABLE 54 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH2015 (JAPAN)TABLE 55 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015(JAPAN)TABLE 56 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH2015 (BRAZIL)TABLE 57 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH2015 (BRAZIL)TABLE 58 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015(BRAZIL)TABLE 59 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH2015 (CHINA)TABLE 60 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH2015 (CHINA)TABLE 61 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015
  • 29. (CHINA)TABLE 62 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH2015 (INDIA)TABLE 63 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH2015 (INDIA)TABLE 64 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015(INDIA)TABLE 65 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH2015 (RUSSIA)TABLE 66 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH2015 (RUSSIA)TABLE 67 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015(RUSSIA)TABLE 68 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH2015 (SOUTH AMERICA)TABLE 69 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH2015 (SOUTH AMERICA)TABLE 70 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015(SOUTH AMERICA)TABLE 71 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH2015 (CARRIBEAN)TABLE 72 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH2015 (CARRIBEAN)
  • 30. TABLE 73 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015(CARRIBEAN)TABLE 74 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH2015 (NORTHERN EUROPE)TABLE 75 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH2015 (NORTHERN EUROPE)TABLE 76 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015(NORTHERN EUROPE)TABLE 77 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH2015 (CENTRAL & EASTERN EUROPE)TABLE 78 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH2015 (CENTRAL & EASTERN EUROPE)TABLE 79 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015(CENTRAL & EASTERN EUROPE)TABLE 80 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH2015 (AUSTRALIA)TABLE 81 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH2015 (AUSTRALIA)TABLE 82 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015(AUSTRALIA)TABLE 83 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH2015 (ASIA-OTHER)TABLE 84 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH
  • 31. 2015 (ASIA-OTHER)TABLE 85 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015(ASIA-OTHER)TABLE 86 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH2015 (MIDDLE EAST)TABLE 87 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH2015 (MIDDLE EAST)TABLE 88 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015(MIDDLE EAST)TABLE 89 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH2015 (SOUTHERN AFRICA)TABLE 90 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH2015 (SOUTHERN AFRICA)TABLE 91 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015(SOUTHERN AFRICA)TABLE 92 APPROVED PRODUCT FORECAST, 2010 AND 2015 ($MILLIONS)TABLE 93 MULTAQ SNAPSHOTTABLE 94 XARELTO SNAPSHOTTABLE 95 EFFIENT SNAPSHOTTABLE 96 RENDIX SNAPSHOTTABLE 97 APIXABAN SNAPSHOTTABLE 98 BRILINTA SNAPSHOT
  • 32. TABLE 99 CERTRIAD SNAPSHOTTABLE 100 LCZ696 SNAPSHOTTABLE 101 EDOXABAN (DU-176B) SNAPSHOTTABLE 102 SCH530348 SNAPSHOTTABLE 103 TYRISA SNAPSHOTTABLE 104 BETRIXABAN SNAPSHOTTABLE 105 PFIZER’S CARDIOVASCULAR PIPELINETABLE 106 SANOFI-AVENTIS’ CARDIOVASCULAR PIPELINETABLE 107 NOVARTIS’ CARDIOVASCULAR PIPELINETABLE 108 MERCK’S CARDIOVASCULAR PIPELINETABLE 109 BMS’ CARDIOVASCULAR PIPELINETABLE 110 ASTRA-ZENECA’S CARDIOVASCULAR PIPELINETABLE 111 COMPANY REVENUE AND MARKET SHARE ANALYSIS,2007-2009 ($ MILLIONS)TABLE 112 MARKET FORECAST BY COMPANY, THROUGH 2015 ($MILLIONS)LIST OF FIGURESSUMMARY FIGURE GLOBAL CARDIOVASCULAR FORECAST BYDISEASE CLASS, 2007-2015 ($ MILLIONS)FIGURE 1 LEADING CAUSES OF DEATH IN THE UNITED STATES;2006 (DEATHS PER 100,000)
  • 33. About Us:ReportsnReports is an online library of over 100,000+ market research reports andin-depth market research studies & analysis of over 5000 micro markets. Weprovide 24/7 online and offline support to our customers. Get in touch with us foryour needs of market research reports.Follow us on Twitter: http://twitter.com/marketsreportsOur Facebook Page:http://www.facebook.com/pages/ReportsnReports/191441427571689Contact:Mr.Priyank7557 Rambler road,Suite727,Dallas,TX75231Tel: + 1 888 391 5441E-mail: sales@reportsandreports.comhttp://www.reportsnreports.comVisit our Market Research Blog

×